 | | Nutrition, Obesity, Diabetes and CVD: exploring mechanisms and consequences Atherosclerosis in the era of widespread metabolic dysregulation |
|  | | Atherosclerosis in the era of widespread metabolic dysregulation Dr JT Tamsma, internist- vasculaire geneeskunde LUMC |
|
 | | Atherosclerosis |
|  | | Atherosclerosis: changing natural history |
|
 | | Primaire Preventie HVZ |
|  | | Traditionele RF |
|
 | | Traditionele RF en atherosclerose |
|  | | Primaire Preventie HVZ |
|
 | | Relevantie “de rest” |
|  | | Metabolic Syndrome – IDF criteria |
|
 | | MS: cardiovascular mortality |
|  | | De beperkingen van MS |
|
 | | Associated Factors: pathofysiologie |
|  | | Het Vervolg |
|
 | | Grundy NRDD 2006 |
|  | | Grundy NRDD 2006 |
|
 | | Grundy NRDD 2006 |
|  | | Metabolic dysregulation & atherosclerosis |
|
 | | Visceral obesity |
|  | | Etiologische momenten MS en atherosclerose |
|
 | | IDF vs NCEP criteria vs mortality |
|  | | Fat & Insulin Resistance |
|
 | | Visceral Adipose tissue inflammation |
|  | | Fat and Systemic Inflammation |
|
 | | Athero – inflammation (local & systemic) |
|  | | Low grade systemic inflammation: CRP |
|
 | | Metabolic dysregulation & atherosclerosis: 2009 |
|  | | Prevalences and associations of these phenotypes |
|
 | | Metabolic dysregulation and Atherosclerosis |
|  | | Rijswijk: visceral obesity dominates metabolic profile |
|
 | | Rijswijk: visceral obesity dominates metabolic profile |
|  | | Atherosclerosis? |
|
 | | Does Inflammation change vascular phenotype in Visceral Obese patients |
|  | | Endpoint: 3T Carotid MRI |
|
 | | 10 slides per patient |
|  | | Quantification wall thickness (VesselMass) |
|
 | | Alizadeh Dehnavi R, Atherosclerosis 2008 200 417 |
|  | | CRP associated will maximal wall thickness in visceral obese patients |
|
 | | Conclusion |
|  | | Does Inflammation change vascular phenotype in Visceral Obese patients |
|
 | | Alizadeh Dehnavi R, Atherosclerosis 2008 200 417 |
|  | | Causality of individual factors for Multifactorial Diseases |
|
 | | Koch’s postulates |
|  | | Brown: Cholesterol is causally related to atherosclerosis |
|
 | | Lazar Nature Medicine 2006 12 43 |
|  | | VO & CRP: Hepatic inflammatory response |
|
 | | Metabolic dysregulation & atherosclerosis |
|  | | VO & Hepatic inflammatory response atherosclerosis |
|
 | | LIKK mouse model |
|  | | APOE*3-Leiden.LIKK mouse model |
|
 | | APOE*3-Leiden.LIKK mouse model |
|  | | Hypothesis |
|
 | | LIKK aggravates atherosclerotic lesion severity |
|  | | LIKK increases atherosclerotic lesion size |
|
 | | Conclusion |
|  | | Widespread metabolic dysregulation & atherosclerosis |
|
 | | In Summary: A clinicians view on atherosclerosis |
|  | | Acknowledgements |
|
 | | Slide 59 |
|  | | South Asian (Hindustani) subjects are at increased risk of CVD and Diabetes |
|
 | | South Asian (Hindustani) subjects are at increased risk of CVD and Diabetes |
|  | | South Asian (Hindustani) subjects are at increased risk of CVD and Diabetes |
|
 | | Slide 63 |
|  | | Slide 64 |
|
 | | EC |
|  | | Atherosclerosis |
|
 | | Atherosclerosis |
|  | | Atherosclerosis |
|
 | | Diagnosis Primary Prevention |
|  | | Cholesterol - statins |
|
 | | Koch’s postulates |
|  | | Brown: Cholesterol is causally related to atherosclerosis |
|
 | | Change central step in atherogenesis |
|  | | Change central step in atherogenesis |
|
 | | Statins: regression plaque? |
|  | | Statins: regression plaque |
|
 | | Statins: Reversal-study |
|  | | LDL & inflammation lowering: regression |
|
 | | Summary |
|  | | Remaining Clinical Challenges |
|
 | | Clinical approaches LDL-c |
|  | | Antisense- A New Drug Class - |
|
 | | ISIS 301012 (Mipomersen) for Cardiovascular Disease |
|  | | Remaining Clinical Challenges II |
|
 | | HDL-cholesterol important target |
|  | | HDL-cholesterol important target |
|
 | | HDL-cholesterol important target |
|  | | HDL-Triglycerides |
|
Deel deze pagina met collega's en vrienden: